Acamprosate Complements Ill-Sustained Response of ECT in Catatonic Fronto-temporal Dementia

Ahmed Naguy*, Ali Al-Tajali1 and Haya al-Mutairi2

1Child and Adolescent Psychiatrist Centre for Mental Health, Kuwait
2General Adult Psychiatrist of Neuromodulation Unit, KCMH, Kuwait

Keywords: Frontotemporal dementia; Catatonia; ECT; Acamprosate

To The Editor

It is estimated that 10-15% of demented patients have clinical characteristics suggestive of Fronto-temporal dementia (FTD) or Pick’s disease. It is the third most common neurodegenerative cortical dementia after Alzheimer’s disease and diffuse Levy’s Body disease. It equally affects both males and females, within the age group of 45-65 years. It manifests mainly as insidious onset of behavioral and personality changes. MRI characteristically shows parietal and anterior temporal lobar atrophy. Psychiatric aspects seem to respect the patterns of classical frontal lobe syndromes. Speech and language abnormalities often begin early and progress rapidly. Incontinence can occur early. Parkinsonism could be an association too. Examination is usually remarkable for witzelsucht, echo phenomena, primitive reflexes, gegenhalten, logopenia, anomia, perseverations but with relatively spared visuo-spatial skills and eventually lack of insight [1,2]. Catatonia, coined historically by Kahlbaum, could complicate this opportunity, if any as the impact in toto could be tremendous [13]. Most experts agree that catatonia is exceedingly underdiagnosed in neuropsychiatric community. This is especially true in the case of FTD, where clinical distinction between both could be too arduous in which cases therapeutic testing with lorazepam or even ECT could be diagnostic [5,6]. It should be borne in mind; however, that catatonia and dementia are not mutually exclusive diagnoses and its implication in “frail” demented patients. Catatonia is anti-craving agent in alcoholism with a putative NMDA-gluatmate antagonistic activity and GABAa enhancing activity [16]. In theory, it neatly fits with neurobiologic model of catatonia. Having said so, we report the following case of catatonic FTD that responded initially to ECT but this was short-lived ill-sustained response where addition of acamprosate resulted in well-sustained outcome. Interestingly, this was achieved with high tolerability and safety given that acamprosate has no effect on hepatic microsomal system.

A 59-year-old Kuwaiti male, long diagnosed as FTD, with a residential placement in Psycho-geriatrics Unit, a known controlled hypertensive, maintained on sertraline 50 mg/d to help obvious apathy, was noted to be progressively psychomotorically sluggish, almost totally mute, resistive, negativistic, occasional stereotypes and paratonia on exam. Diagnosis of superimposed catatonia was entertained. A therapeutic test with IM lorazepam was positive. A course of ECT was suggested and discussed with care-givers. After 5 sessions of modified bitemporal ECT, a tangible improvement was noted but unfortunately, ill-sustained. We splitted over pursuing further with ECT or employing high-dose lorazepam strategy but both were detracting in terms of cognitive drawbacks and past history of pulmonary embolism for the latter. We thought of embarking on a trial with acamprosate for its pharmacologic portfolio and benign side-effects as well. Caregivers consent was obtained beforehand. We dosed it at 333 mg tds. Over next few days, catatonia markedly abated and response was well-sustained. This was achieved with high tolerability. After a couple of weeks, we attempted at withdrawing acamprosate, patient readily slipped into catatonoid state that resolved rapidly when acamprosate was reinstitted at same dosage. The patient fared well over next 6 months. Buch-Francis Catatonia Rating Scale at baseline (read 39) and follow-ups (dropped to 8) was used all through to objectify clinical findings.

To our knowledge, this is one of first cases reporting utility of acamprosate in catatonia, which could open new venues for treatment when first-line treatments are ineffective or intolerable especially in geriatric population with already compromised cognitions. And certainly, well-designed trials are needed to draw definite conclusions about the use of acamprosate in catatonia.
Disclosures

Authors declare no conflicts of interest.

References


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:
- 400 Open Access Journals
- 30,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://www.editorialmanager.com/psychiatry/